Research programme: micro-dose serotonergics - Gilgamesh Pharmaceuticals
Latest Information Update: 20 May 2021
At a glance
- Originator Gilgamesh Pharmaceuticals
- Class Antidepressants; Behavioural disorder therapies
- Mechanism of Action Serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Attention-deficit hyperactivity disorder; Major depressive disorder